About Hualan Biological Vaccine Inc. Company

The company was founded in 2005 and is a high-tech enterprise engaged in the development, production and sale of vaccine products. It is the birthplace of the first batch of influenza A (H1N1) vaccines marketed in the world. It is the fifth company in the world and the first company in China to pass WHO pre-certification for influenza vaccines. The company has fully passed the “ISO” management system certification for quality, environment, and occupational health and safety, and has a number of independent intellectual property rights. The leading products lead the development of the domestic industry with their advantages in production scale, market share, and brand influence. The company is mainly engaged in the production, development and sales of human vaccines. The company's main products are influenza virus lysis vaccine, quadrivalent influenza virus lysis vaccine, H1N1 influenza virus lysis vaccine, ACYW135 meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hanson yeast), group A group C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. Company honors: China's AAA credit enterprise title, “Eleventh Five-Year Plan” National Science and Technology Program Implementation Outstanding Team Award, Hualan Biological Influenza Vaccine passed Ukrainian GMP certification, etc.